We envision a world without a risk for renal toxicity for compounds entering clinical stages of drug development.

Cell4Pharma aims to reduce the failure rate in late clinical stages due to renal tox below 3% market wide within the next 10 years. Without the use of animal experimentation.

This ambition is supported by our human renal cell line ciPTEC validated during extensive collaborations with the pharmaceutical industry. More than 10 years of research lead to the development of robust cell-based assays focusing on the detection of highly specific biomarkers for renal toxicity.

Cell4Pharma

Org chart

Teams

Offices